Form 4: Corcept Therapeutics Director Joshua M. Murray Acquires 30,000 Stock Options

Director Joshua M. Murray of Corcept Therapeutics acquired 30,000 stock options on May 17, 2024, exercisable over a one-year period.

Summary

• On May 17, 2024, Joshua M. Murray, a director of Corcept Therapeutics, acquired 30,000 stock options.
• The exercise price of these options is $28.09.
• The options become exercisable ratably in equal monthly installments over a one-year period, starting May 17, 2024.
• The options expire on May 16, 2034.
• Following the transaction, Murray directly owns 30,000 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock option grants to a director, which is a common practice. It doesn't inherently indicate positive or negative sentiment, but rather a standard part of executive compensation.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders, like directors and officers, trade their company's securities. These filings provide transparency into insider transactions and can be monitored for insights into management's perspective on the company's value and prospects.

Stakeholder Impact

• The acquisition of stock options by a director aligns their interests with those of shareholders, potentially incentivizing them to work towards increasing shareholder value.

Key Dates